Activating molecule in Beclin-1-regulated autophagy (Ambra1) • Breast cancer • Microarray • RNA sequencing • Knock-down Abstract Background/Aims: The activating molecule in Beclin1-regulated autophagy (Ambra1) has been observed to be over-expressed in several cancers, but the clinical contribution of Ambra1 in breast cancer (BC) remains unknown. Hence, in this study, we conducted a comprehensive investigation into the expression, biological role, and underlying functional mechanism of Ambra1 in BC. Methods: Microarray and RNA-seq datasets providing Ambra1 expression data were obtained from Gene Expression Omnibus (GEO), ArrayExpress, Oncomine, and The Cancer Genome Atlas (TCGA). Both standard mean deviation (SMD) and summary receiver operating characteristic methods were employed to assess Ambra1 expression in BC. We then silenced Ambra1 in MDA-MB-231 cells and performed in vitro experiments to explore the biological effects of Ambra1 on BC cells. Furthermore, differentially expressed genes (DEGs) after Ambra1 knock-down were profiled with a microarray and overlapped with the genes correlated with Ambra1 from Multi Experiment Matrix (MEM) and genes similar to Ambra1 from Gene Expression Profiling Interactive Analysis. These overlapping genes were collected for further bioinformatics analyses to investigate the underlying molecular mechanism of Ambra1 in BC. Results: A total of 25 microarray and RNA-seq datasets involving 2460 breast cancer samples were included. The pooled results demonstrated that Ambra1 was markedly up-regulated in BC tissues (SMD=0.39, 95% CI=0.15-0.63; P=0.002), and the Ambra1 level was also significantly related to the progression of BC, especially metastasis status (P=0.004).
Introduction
Autophagy, an essential eukaryotic process of self-digestion, is associated with the lysosomal degradation of cytosolic components and can occur in physiological or pathological circumstances. Of interest, autophagy can serve contradictory roles in tumor promotion and suppression. A number of crucial proteins are involved in the process of autophagy, including BECN1/Beclin 1 and activating molecule in Beclin1-regulated autophagy (Ambra1), which is a positive regulator of Beclin1 [1] [2] [3] . Ambra1, a WD40 domain-containing protein, has been documented to be involved in the growth and progression of the central nervous system, adult neurogenesis, and vertebrate embryogenesis [4] . Ambra1 can be adversely modulated by mTOR phosphorylation, which inhibits binding to the E3-ligase TRAF6 and ULK1 ubiquitylation, therefore modulating the stability and function of ULK1 [5, 6] . Moreover, Ambra1 is able to bind c-Myc to the phosphatase PP2A, which finally leads to c-Myc degradation, decreased cell growth, and carcinogenesis [7] [8] [9] .
Concurrently, Ambra1 has been observed to be over-expressed in several cancers, including pancreatic ductal adenocarcinoma (PDAC) [10] , cholangiocarcinoma [11] , prostate cancer [12] , cutaneous melanoma [13] , and gastric adenocarcinoma [14] . Furthermore, the clinicopathological effect of Ambra1 has also been reported in several malignancies. Accumulation of Ambra1 appeared to be related to the status of lymph node metastasis and worse survival of cholangiocarcinoma patients [11] . Up-regulated Ambra1 was also positively associated with the Gleason score in prostate cancer [12] . Ambra1 was further identified to be a new independent prognostic marker for early stage melanomas [13] . Most recently, a high level of Ambra1 was found to be significantly correlated with depth of invasion and lymph node metastasis in gastric adenocarcinoma (GC) [14] . More importantly, an increase in Ambra1 level could be an independent predictor of worse survival in GC patients. These findings suggest that the occurrence of autophagy via Ambra1 could be associated with a malignant phenotype and progression in several malignancies.
Breast cancer (BC) is the most common malignancy among females worldwide, and is a heterogeneous and multiplex disease with multiple pathogenic factors [15] [16] [17] . The 5-year survival of BC will be greatly improved if the disease is diagnosed at an early stage, yet the outcome of 15% of BC patients is still poor due to diagnosis at an advanced stage [18] [19] [20] [21] [22] . Based on estrogen and progesterone receptors, human epidermal growth factor receptor type 2 (HER2) and Ki-67, BC patients have been categorized into different subtypes, including luminal A, luminal B, Her2 over-expressing (Her+), and triple negative breast cancer subtypes, which are sensitive to various treatment regimens [23] [24] [25] [26] . Nevertheless, treatment algorithms do not definitely give rise to favorable clinical outcomes. Consequently, sensitive and accurate predictive biomarkers are needed to improve prognosis and treatment efficacy [27] [28] [29] [30] .
The functions and mechanisms involved in autophagy in BC cells have been extensively investigated [31] [32] [33] . However, understanding of the prospective role of Ambra1 in BC remains limited. Only one study conducted by Shen et al [34] . showed that cisplatin induced autophagy in BC cells and up-regulated multiple autophagy-related genes, including Ambra1. Hence, in the present study, we conducted a comprehensive investigation of Ambra1 expression based on high-throughput data from different sources, including the Gene Expression Omnibus (GEO), ArrayExpress, Oncomine, and The Cancer Genome Atlas (TCGA). We then silenced Ambra1 in MDA-MB-231 cells and performed in vitro experiments to explore the biological effects of Ambra1 on BC cells. Furthermore, the differentially expressed genes (DEGs) after Ambra1 knock-down were profiled with a microarray and overlapped with the Ambra1-correlated genes from Multi Experiment Matrix (MEM) and genes similar to Ambra1 from Gene Expression Profiling Interactive Analysis (GEPIA). These overlapped genes were collected for further bioinformatics analyses to investigate the underlying molecular mechanism of Ambra1 in BC.
Materials and Methods
Studies based on data from GEO, ArrayExpress, Oncomine, and TCGA: Data downloading and processing from GEO, ArrayExpress, Oncomine, and TCGA BC-related mRNA microarray datasets were collected from GEO (http://www.ncbi.nlm.nih.gov/ geo/), ArrayExpress (http://www.ebi.ac.uk/arrayexpress/), and Oncomine (https: //www. oncomine.org/ resource/main.html) up to January 6, 2018. Search strategy was ((breast OR mammary OR mastocarcinoma) AND (cancer OR carcinoma OR tumor OR neoplas* OR malignan*) AND (mRNA OR gene OR protein)). Additionally, we retrieved Ambra1-related RNA-seq datasets and corresponding clinical and survival data from TCGA (http://cancergenome.nih.gov/) to evaluate the clinical significance of Ambra1 in BC.
The following inclusion criteria were applied to select eligible datasets: (1) human research; (2) both BC samples and normal controls were included in each dataset; (3) each group comprised no less than three samples; and (4) Ambra1 expression data in each group were provided.
Essential information such as data source, platform, first author, publication year, sample size, and Ambra1 expression level in both cancer and normal control groups was collected by two reviewers independently (Rong-quan He and Dan-dan Xiong). In the case of disagreement, these reviewers would consult with a third investigator (Gang Chen).
Statistical analysis
All Ambra1 expression data were log2-transformed. The expression pattern and diagnostic capability of Ambra1 in each included dataset were visualized in the form of scatter plots and receiver operating characteristic (ROC) diagrams using GraphPad Prism 5 (La Jolla, CA) and SPSS 20.0 (IBM, Armonk, NY). Next, we integrated all individual datasets. A combined standard mean deviation (SMD) was calculated and a summary receiver operating characteristic (SROC) curve was generated with STATA 12.0 (Stata Corporation, College Station, TX were cultured at 37°C in RPMI-1640 supplemented with 10% fetal calf serum, 100 units/mL penicillin, and 100 μg/mL streptomycin in a humid incubator with 5% CO 2 . Specific-target Ambra1 sh-RNA (2450) and control scrambled plasmids were synthesized by GenePharma (China). The sequence of 2450 was GCT GGA ATC TTC CCT CAT TTC. The plasmids were transfected into MDA-MB-231 cells using Lipofectamine TM 2000 (Invitrogen, Carlsbad, CA). To assay the knock-down effects on Ambra1, the proteins were detected using Western blotting after transfection with the plasmids for 48 h. Rabbit polyclonal anti-Ambra1 (sc-130116) was obtained from Santa Cruz Biotechnology, Inc., Dallas, TX. Goat polyclonal anti-rabbit GAPDH (MAB5465) was purchased from MultiSciences (Lianke) Biotech Co., Ltd., Hangzhou, China.
Cell proliferation and apoptosis
Cells were seeded at 8 × 10
3 cells per well in 96-well flat-bottomed plates (Corning, Corning, NY) and were allowed to attach overnight at 37°C. Then, appropriate medium was added to each well and cells were further cultured at 37°C for the indicated times. The numbers of viable and apoptotic cells were estimated using the cell counting kit-8 (CCK-8; Dojindo Molecular Technologies, Inc., Kumamoto, Japan). Absorbance was measured at 450 nm with a microplate reader (Bio-Rad Laboratories Inc., Hercules, CA). Results are from three independent experiments for each group. Statistical analysis was performed using SPSS 22.0 (IBM, Armonk, NY). Significance between groups was analyzed via independent sample t-test. P<0.05 was considered statistically significant.
DEGs after Ambra1 knock-down in BC MDA-MB-231 cells
BC MDA-MB-231 cells with and without Ambra1 knock-down were used for microarray detection with OneArray (http://www.OneArray.com, PhalanxBio, Inc. San Diego, CA). All mRNAs were annotated according to NCBI RefSeq release 70 and Ensembl release 80 cDNA sequences. Array data were processed using Limma (Bioconductor). The DEGs were required to meet the following criteria: log2 |Fold change| ≥ 1 and P<0.05.
Bioinformatics analysis
Collection of genes co-expressed with and similar to Ambra1. Genes co-expressed with Ambra1 were collected from MEM (http://biit.cs.ut.ee/mem/index.cgi). Genes similar to Ambra1 were collected from GEPIA (http://gepia.cancer-pku.cn/).
Functional annotation and protein-protein interaction (PPI) network construction.
To further explore the underlying molecular mechanism of Ambra1 in BC, we collected overlapping genes from co-expressed genes and DEGs for further Gene Ontology (GO) annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses. We also constructed a PPI network based on these overlapping genes using the STRING (http://www.string-db.org/). In addition, we obtained overlapping genes from co-expressed genes, DEGs, and similar genes for further gene set enrichment analysis using the GSEA (http://software. broadinstitute.org/gsea/msigdb/collections.jsp#H) database.
Results
In this study, we conducted a comprehensive analysis of the potential role of Ambra1 in BC. The overall design of this study is shown in Fig. 1 .
Expression level of Ambra1 in BC
A total of 25 microarray and RNA-seq datasets involving 2460 BC samples and 531 normal controls were included in our study, and information from these eligible studies is presented in Table 1 . The expression levels of Ambra1 in individual datasets are displayed as scatter plots and ROC curves (Fig. 2-3 
Clinical significance and prognostic value of Ambra1 in BC
Relationships between Ambra1 expression and clinicopathological parameters are shown in Table 2 . We found that Ambra1 expression was significantly correlated with age (P=0.023; Fig. 6A ), estrogen receptor (ER) status (P<0.0001; Fig. 6B ), progesterone receptor (PR) status (P=0.001; Fig. 6C ), M stage (P=0.004; Fig. 6D ), and molecular subtype (Fig. 6E) . However, no clear correlations were found between Ambra1 expression and gender, HER2 status, TNM stage, T stage, and N stage.
The prognostic role of Ambra1 in BC was explored based on data from the TCGA and Kaplan-Meier plot (http://kmplot.com/analysis). However, the results showed no statistically significant relationship between Ambra1 expression and survival outcome in patients with BC ( Fig. 6F-6I) .
Additionally, alteration of Ambra1 in BC was explored using data from cBioPortal (http://www.cbioportal.org/), a public database that collects and processes data from TCGA. We found that the alteration rate of Ambra1 in BC was 1.6% (Fig. 6J) . 
Fig. 2. Scatter plots evaluating the expression level of Ambra1 in breast cancer (BC) (A) GSE54002, (B) GSE61723, (C) GSE29431, (D) GSE22544, (E) GSE15852, (F) GSE25407, (G) GSE10780, (H) GSE7904, (I) GSE6883, (J) GSE65194, (K) GSE42568, (L) GSE10870, (M) GSE10797, (N) GSE5764, (O) GSE61724, (P) GSE61304, (Q) GSE33692, (R) GSE21422, (S) GSE36295, (T) TCGA, (U) Oncomine (Finak G), (V) Oncomine
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Effects of Ambra1 on cell proliferation and apoptosis
The target-specific Ambra1 sh-RNA 2450 was transfected into MDA-MB-231 cells; the knock-down efficiency was 60% as detected by Western blotting (Fig. 6K ). Viable and apoptotic cells were examined using CCK-8 (Dojindo Molecular Technologies, Inc.). The proliferation of MDA-MB-231 cells transfected with Ambra1 sh-RNA 2450 showed a decreasing trend at 48 h compared with the CK group (Fig. 6L) . Apoptosis was similar in cells transfected with Ambra1 sh-RNAs and CK cells (Fig. 6M) .
Collection of DEGs and co-expressed genes
DEGs after Ambra1 knock-down were analyzed using microarray and 828 genes were found, comprising 71 up-regulated and 757 down-regulated genes ( Supplementary Fig. S1A -1B -for all supplemental material see www.karger.com/10.1159/000495483). Genes that were co-expressed with Ambra1 were downloaded from the MEM database, and four probes (234237_S_AT, 52731_AT, 234236_AT, and 219141_S_AT) were applied ( Supplementary Fig.  S2-5) . Genes that were detected in at least two probes were considered co-expressed with Ambra1. A total of 4266 co-expressed genes were selected for further analysis. 
(A) GSE54002, (B) GSE61723, (C) GSE29431, (D) GSE22544, (E) GSE15852, (F) GSE25407, (G) GSE10780, (H) GSE7904, (I) GSE6883, (J) GSE65194, (K) GSE42568, (L) GSE10870, (M) GSE10797, (N) GSE5764, (O) GSE61724, (P) GSE61304, (Q) GSE33692, (R) GSE21422, (S) GSE36295, (T)
TCGA
GO and KEGG pathway analyses
From intersection between the 4266 coexpressed genes and the 828 DEGs, we obtained a total of 183 genes, which were selected for GO and KEGG pathway analyses ( Supplementary Fig. S1C ). The most enriched GO and KEGG results are presented in Supplementary Fig. S1D-1G . Results of GO functional annotation indicated that the main biological processes of the 183 overlapping genes were 'metabolic process' (biological process category), 'nucleus' (cellular component category), and 'protein binding' (molecular function category). The results of KEGG pathway analysis indicated that Ambra1 was associated with cancerrelated pathways, such as 'MAPK signaling pathway', 'chronic myeloid leukemia', 'VEGF signaling pathway', and 'pathways in cancer'.
PPI network construction
To better understand the underlying molecular mechanism of the 183 overlapping genes, we established a PPI network using the online tool STRING. With a confidence score greater than 0.4, the PPI network was constructed with 182 nodes and 126 edges ( Supplementary  Fig. S1H ).
Gene Set Enrichment Analysis (GSEA)
A total of 200 genes similar to Ambra1 were downloaded from the GEPIA database. The intersection between the 4266 co-expressed genes, the 828 DEGs, and the 200 similar genes was gathered for GSEA analysis (Fig. S6A) . Twelve overlapping genes (ATG13, PRRC2B, C11orf49, MAPKBP1, CTDSP2, RERE, ZNF629, TMEM127, ZBTB4, TRIM44, RIC8A, and EFCAB14) were uploaded to the GSEA website and the expression levels of the 12 genes in various tissues and cell lines are presented in Fig. S6B -6C . 
Discussion
In this study, we comprehensively investigated the contribution of Ambra1 to BC based on high-throughput data, including GEO, ArrayExpress, Oncomine, and TCGA. Finally, 25 microarray and RNA-seq datasets with 2460 BC samples were included. Ambra1 was found to be markedly up-regulated in BC tissues; furthermore, the Ambra1 level was significantly related to BC progression, especially metastatic status. Subsequently, we performed a microarray after Ambra1 knock-down in vitro and gathered co-expressed genes of Ambra1 from MEM. Eventually, the overlapping 183 genes were found to be enriched in several wellknown cancer-related pathways, which could partially explain the effect of Ambra1 on cell proliferation inhibition in BC cells.
Ambra1 is an autophagy-related gene that can regulate Beclin1. Interplay between Ambra1 and Beclin1 has been reported previously. Here, we found their close correlation in BC based on data from TCGA (Fig. 7A) , suggesting that Ambra1 may interact with Beclin1 [11] . Ambra1 protein expression was investigated by both immunohistochemistry and Western blotting in tissue samples from both benign and malignant prostatic lesions. This pilot study revealed an increase in Ambra1 protein expression [12] . A similar expression pattern of Ambra1 was also reported in GC. Quantum dots immunofluorescence histochemistry was used to detect Ambra1 protein expression in GC tissue microarrays with 163 cancer samples and 20 gastric control tissues. Concurrently, Western blotting was also performed in the 10 paired fresh GC tissues with their controls. Consistent with findings in PDAC, cholangiocarcinoma, and prostate cancer, Ambra1 protein expression was clearly up-regulated in GC compared with non-cancerous gastric controls [14] . To the best of our knowledge, the expression level of Ambra1 has not previously been reported. The relationship between Ambra1 and BC was mentioned in only one previous study. Shen et al [34] . reported that docetaxel and cisplatin could induce autophagy in BC cells. Real-time polymerase chain reaction revealed that cisplatin could upregulate multiple autophagy-related genes, including Ambra1. However, the authors did not focus on the clinical and functional significance of Ambra1 in BC. In the present study, we collected and mined the publicly available high-throughput data to elucidate the potential role of Ambra1 in the tumorigenesis of BC. It is interesting that from 25 microarray and RNA-seq datasets involving 2460 BC samples, the constant up-regulation of Ambra1 could be observed by both SMD and SROC methods, though the individual studies showed some contradictory results. Additionally, the high expression of Ambra1 protein was corroborated by The Human Protein Atlas. Furthermore, data from cBioPortal also suggested that some genetic alterations of Ambra1 could occur in BC, including amplification and deep deletion. These results, for the first time, have shed light on the potential role of Ambra1 in BC. Ambra1 can induce the occurrence of tumors, and the driving role of Ambra1 in the progression of cancers has also been documented. Ambra1 could accumulate in prostate cancer and this high expression of Ambra1 was positively correlated with the Gleason score [12] . The expression of Ambra1 was positively associated with the epithelial-mesenchymal transition (EMT) in cholangiocarcinoma, which could partially explain that up-regulation of Ambra1 was closely associated with lymph node metastasis and poor survival [11] . Based on the findings from this study of cholangiocarcinoma, we examined the relationships between Ambra1 and two well-known EMT markers, TGF-β1 and Smad3. Positive correlations were noted between Ambra1 and these two EMT markers (Fig. 7B-7C ) and the molecular mechanism underlying the influence of Ambra1 on EMT is worthy of in-depth investigation in the future. Moreover, in GC, Ambra1 played a role in accelerating tumor progression, as over-expression of Ambra1 was clearly correlated with the depth of tumor invasion and lymph nodes metastasis. More importantly, over-expression of Ambra1 could be an independent indicator of overall survival of GC patients [14] . Furthermore, the earlier study on primary melanomas revealed a decline or even complete absence of Ambra1 expression in the epidermis overlying many stage I melanomas, which showed no relationship with the degree of melanoma epidermal invasion, and this lower or absent Ambra1 expression was not observed in benign nevi. These facts indicated that Ambra1 expression in the melanoma microenvironment may have prognostic potential. Essentially, this lower or absent Ambra1 expression was predominantly related to worse disease-free survival, with stratification for American Joint Committee on Cancer (AJCC) stage I disease. Thus, epidermal Ambra1 expression could act as a marker of disease progression for primary melanomas [13] . In the present study, we also observed that Ambra1 was greatly over-expressed in young patients with ER-and PR-positive BC. After classifying BC patients into different subtypes by the expression status of ER, PR, and Her2, we found that the expression level of Ambra1 was highest in the luminal A subtype and lowest in the Her2 over-expressing subtype. However, the precise mechanism needs to be further investigated. Surprisingly, Ambra1 expression was significantly higher in M0 stage than in M1-3 stage BC, which was inconsistent with findings in cholangiocarcinoma and GC. The biological function of Ambra1 may be tumorspecific. We also attempted to assess the prognostic role of Ambra1 in BC, but no significant results were obtained. Larger cohorts are required to further validate the current findings.
From the clinical observation above, we are interested in the mechanism of action of Ambra1 in the tumorigenesis and progression of BC. We therefore performed in-house microarray after Ambra1 knock-down in BC cells in vitro, which led to a slight suppression of cell proliferation. Altogether, 828 DEGs were obtained. To enhance the specificity of Ambra1-related genes, we gathered another group of 4266 co-expressed genes. Finally, the overlapping 183 genes were particularly enriched in several cancer-related pathways, including the MAPK signaling pathway, chronic myeloid leukemia, the VEGF signaling pathway, and pathways in cancer. Ambra1 may influence these well-known pathways and thereby affect the incidence and progression of BC. However, the molecular mechanism underlying the influence of Ambra1 in BC requires further in vitro and in vivo investigation.
Autophagy is the principal lysosomal-mediated process for the degradation/recycling of cellular debris and is a topic of intense debate in cancer medicine. In this study, we applied multiple detection methods to confirm that Ambra1, a vital autophagy-related gene, is upregulated in BC tissues. The driving role of Ambra1 in the incidence and development of BC could be implemented via influencing several well-explored signaling pathways. However, the clinical significance of Ambra1 detection needs to be validated with more in-depth research.
